Literature DB >> 3971474

Time-schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay.

Y Matsushima, F Kanzawa, A Hoshi, E Shimizu, H Nomori, Y Sasaki, N Saijo.   

Abstract

To analyze the discrepancy between the in vitro response in the clonogenic assay and the clinical response, the time-schedule dependencies of various anticancer drugs were determined by comparing the inhibiting effect against colony formation by PC-7 cells treated with the drugs for 1 h with that of those treated for 24 h. According to their schedule dependency the drugs can be divided into a schedule-dependent drug group (5-fluorouracil, methotrexate, bleomycin, pepleomycin, etoposide, cisplatin, teniposide, vindesine, and vinblastine) and a non-schedule-dependent drug group (adriamycin, actinomycin D, ranomustine, mitomycin C, aclacinomycin, daunomycin, nimustine, melphalan, and KW 2083). In the clonogenic assay, the 1-h exposure schedule is appropriate for predicting clinical response for the non-schedule-dependent drugs. However, the effect of the schedule-dependent drugs was underestimated in the same conditions. Therefore, it is necessary to test these drugs in the assay by 24-h exposure for a more accurate assessment of their antitumor activity.

Mesh:

Substances:

Year:  1985        PMID: 3971474     DOI: 10.1007/bf00434345

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  17 in total

Review 1.  DEVELOPMENT, MAINTENANCE AND ASSAY OF DRUG RESISTANCE.

Authors:  G A FISCHER; A C SARTORELLI
Journal:  Methods Med Res       Date:  1964

Review 2.  Are cell kinetic data relevant for the design of tumour chemotherapy schedules?

Authors:  L M van Putten
Journal:  Cell Tissue Kinet       Date:  1974-09

3.  Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay.

Authors:  R Ludwig; D S Alberts; T P Miller; S E Salmon
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

4.  Human tumor clonogenic assay in patients with unknown primary carcinomas.

Authors:  B R Greenberg; S E Salmon
Journal:  J Clin Oncol       Date:  1984-01       Impact factor: 44.544

5.  Human tumor colony assay and chemosensitivity testing.

Authors:  S E Salmon
Journal:  Cancer Treat Rep       Date:  1984-01

6.  Concentration and time-dependent inter-relationships for antitumour drug cytotoxicities against tumour cells in vitro.

Authors:  H T Rupniak; R D Whelan; B T Hill
Journal:  Int J Cancer       Date:  1983-07-15       Impact factor: 7.396

Review 7.  The role of the human tumor stem cell assay in medical oncology.

Authors:  P A Johnson; A H Rossof
Journal:  Arch Intern Med       Date:  1983-01

8.  Prospective clinical trial of a human tumor cloning system.

Authors:  D D Von Hoff; G M Clark; B J Stogdill; M F Sarosdy; M T O'Brien; J T Casper; D E Mattox; C P Page; A B Cruz; J F Sandbach
Journal:  Cancer Res       Date:  1983-04       Impact factor: 12.701

9.  Potentials and limitations of a clonogenic cell assay for human brain tumors.

Authors:  M L Rosenblum; D V Dougherty; D F Deen; C B Wilson
Journal:  Cancer Treat Rep       Date:  1981

10.  Mechanism of cytotoxicity of 5-fluorouracil: distinction between the irreversible cytotoxic effect of 5-fluorouridine and the reversible cytotoxic effect of 5-fluoro-2'-deoxyuridine on murine lymphoma L5178Y cells in culture.

Authors:  F Kanzawa; A Hoshi; K Kuretani
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

View more
  16 in total

1.  A mathematical model for cisplatin cellular pharmacodynamics.

Authors:  Ardith W El-Kareh; Timothy W Secomb
Journal:  Neoplasia       Date:  2003 Mar-Apr       Impact factor: 5.715

2.  Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.

Authors:  Joseph A Sparano; Abdissa Negassa; Erick Lansigan; Robin Locke; Chamath R De Silva; Peter H Wiernik
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

Review 3.  Continuous infusion of chemotherapy: focus on 5-fluorouracil and fluorodeoxyuridine.

Authors:  R L Poorter; P J Bakker; C H Veenhof
Journal:  Pharm World Sci       Date:  1998-04

4.  Rapid chemosensitivity testing of human lung tumor cells using the MTT assay.

Authors:  S P Cole
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Effects of defined medium, fetal bovine serum, and human serum on growth and chemosensitivities of human breast cancer cells in primary culture: inference for in vitro assays.

Authors:  J T Emerman; E E Fiedler; A W Tolcher; P M Rebbeck
Journal:  In Vitro Cell Dev Biol       Date:  1987-02

6.  Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel.

Authors:  Hua He; Yanguang Cao
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-08-31       Impact factor: 2.745

Review 7.  Intraperitoneal therapy for peritoneal tumors: biophysics and clinical evidence.

Authors:  Wim P Ceelen; Michael F Flessner
Journal:  Nat Rev Clin Oncol       Date:  2009-12-15       Impact factor: 66.675

Review 8.  Cancer of the esophagus: the Wayne State University experience.

Authors:  L Leichman
Journal:  Invest New Drugs       Date:  1989-04       Impact factor: 3.850

Review 9.  Pharmacokinetic optimisation of treatment with oral etoposide.

Authors:  Giuseppe Toffoli; Giuseppe Corona; Barbara Basso; Mauro Boiocchi
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

10.  Phase II study of cisplatin as a 5-day continuous infusion with vindesine plus recombinant human granulocyte-colony-stimulating factor in the treatment of advanced non-small-cell lung cancer.

Authors:  Y Saito; K Mori; K Tominaga; K Yokoi; N Miyazawa
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.